SOUTH SAN FRANCISCO, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced that Dr. Kenneth Hillan, Chief Executive Officer, has accepted invitations to participate and present at the following conferences in June:
- BIO 2015 - Super Session: Investment Incentives to Combat Antimicrobial Resistance (AMR)
Dr. Hillan will join other renowned panelists to discuss the numerous global initiatives that intend to address the public health crises caused, among other reasons, by the lack of investment in novel antibacterial products by industry. Panelists will discuss the strong momentum within funding, regulatory and commercial environments and the incentives that are most likely to stimulate industry research and development.
Wednesday, June 17th, 2015 – 10:00-11:30am
Pennsylvania Convention Center – Philadelphia, PA
Room #114, Session ID #2401
- Antimicrobial Innovation Alliance (AIA) - Stimulating the Antimicrobial Pipeline: A Global Perspective
Dr. Hillan's presentation, titled "Economic Considerations of a Clinical Stage Company," will provide an industry perspective on the economic challenges around the research, development, and approval of new antimicrobial products, as well as current initiatives such as the DISARM Act that are intended to address these challenges. This event, hosted by the AIA, a diverse coalition of companies in the antibiotics space, and sponsored in coordination with the UK Review on Antimicrobial Resistance, will be attended by members of Congress, as well as leadership representatives from government funding agencies and the White House.
Thursday, June 18th, 2015 – 12:30pm
U.S. Capitol Visitor Center – Washington, D.C.
Room: HVC 201
These appearances will continue Dr. Hillan's leadership in advocating for regulatory and reimbursement reform, including the DISARM Act. The DISARM Act (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms), which recently advanced out of committee in the House of Representatives as part of the 21st Century Cures Act, would reform reimbursement of qualifying antimicrobial products in the hospital setting to allow value-based pricing, thus providing a powerful incentive for manufacturers to develop new antibiotics.
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious lung, bloodstream, and urinary tract infections due to Enterobacteriaceae, including, but not limited to, carbapenem-resistant Enterobacteriaceae (CRE). Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
CONTACT: Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 105 email@example.com